Building the Evidence for Systemic Treatment in Desmoid Fibromatosis: Is a New Metronomic Regimen Another Layer in the Foundation?

JCO Glob Oncol. 2024 May:10:e2300488. doi: 10.1200/GO.23.00488.

Author

Thierry Alcindor¹

Affiliation

¹ Center for Sarcoma, Center for Global Cancer Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

PMID: 38723215
DOI: 10.1200/GO.23.00488

Abstract

@Thalcin explains how a metronomic regimen for desmoid tumors fits in the current treatment landscape.

Publication types

Editorial

MeSH terms

Administration, Metronomic*
Fibromatosis, Aggressive* / drug therapy
Humans